Applications

1819 – Lisocabtagene maraleucel (Breyanzi) for the treatment of large B-cell lymphoma

Find out about the service or technology in application 1819 and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input, and the outcome of the application when the MSAC process is complete.

  • Status Assessment
  • Type New application
  • Pre-PASC consultation Not applicable
  • Pre-MSAC consultation Open
  • Outcome Pending

Application details

Applicant

Bristol-Myers Squibb Australia Pty Ltd

Reason for application

Funding for a high cost, highly specialised therapy under the National Health Reform Agreement

Service or technology in this application

Lisocabtagene maraleucel (Breyanzi) is a type of treatment called CAR-T cell therapy. This treatment is made using a patient’s own T‑cells, which are a type of immune cell. This means the treatment is specially made for each person.

To make CAR‑T cells, doctors first collect the patient’s T‑cells from their blood. These cells are then sent to a laboratory, where they are modified so they recognise and attack cancer cells. The patient's modified T‑cells are grown into larger numbers and then put back into the patient through an IV infusion. Once inside the body, the modified cells seek out and destroy cancer cells.

Type: Therapeutic technology

Medical condition this application addresses

Large B-cell lymphoma (LBCL) is a type of blood cancer that arises from lymphocytes (a type of white blood cell), which are part of the body’s immune system.

Large B-cell lymphoma typically starts as a quick growing mass in a lymph node but can also start in other areas, such as the intestines, bones, or even the brain or spinal cord.

Consultation survey and deadlines

The following consultation deadlines apply:

  • Pre-PASC consultation deadline: Bypassing PASC
  • Pre-MSAC consultation deadline: Friday 9 October 2026 11:59 pm AEDT

We welcome input from everyone. We are especially keen to hear from those with lived experience of the health condition, service or technology the applications are addressing. 

To provide input, go to the relevant application page and select the ‘provide your input online’ button. For other ways to provide input, see how to have your say. Before providing your input, please read the Privacy notice for MSAC consultation input to ensure you are comfortable with how we will use your input.

Find out more about consultation.

Meetings to consider this application

This application will be considered at the following meetings:

  • PASC meeting: Bypassing PASC
  • ESC meeting: 8 to 9 October 2026
  • MSAC meeting: 26 to 27 November 2026

Find out more about our meetings.

Outcome details

The outcome of this application is pending.

More information

Find out more about: